Pantogam active capsule 300mg, No. 60

Cognitive impairments in organic brain lesions (including the consequences of neuroinfections and traumatic brain injuries) and neurotic disorders;

cerebrovascular insufficiency caused by atherosclerotic changes in the vessels of the brain;

extrapyramidal hyperkinesis (myoclonus epilepsy, Huntington's chorea, hepatolenticular degeneration, Parkinson's disease, etc.), as well as for the treatment of extrapyramidal syndrome caused by the use of antipsychotics; with epilepsy, together with anticonvulsants;

psycho-emotional overload, decreased mental and physical performance, to improve concentration and memorization; neurogenic urination disorders (pollakiuria, urgency, urinary incontinence, enuresis); with schizophrenia in complex therapy.

Inside, 15-20 minutes after meals, 1-3 capsules (0.3-0.9 g) 2-3 times a day, preferably in the morning and afternoon. The maximum daily dose is 8 capsules (2.4 g). The course of treatment is 1-4 months, sometimes up to 6-12 months. A second course of treatment is possible in 3-6 months.

1 capsule contains:

Active ingredient: rac-Hopantenic acid (D, L-Hopantenic acid) 300.0 mg;

Excipients: microcrystalline cellulose 20.97 mg, magnesium stearate 1.53 mg; hard gelatin capsules No. 0 (capsule composition: titanium dioxide 2%, gelatin up to 100%).

Hypersensitivity, acute severe kidney disease, patient age up to 18 years (there are no clinical studies on the use of the drug at an earlier age).

Application during pregnancy and during breastfeeding

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Trade name of the drug:

Pantogam asset

Grouping name:

D, L-Hopantenic acid (active substance: rac-hopantenic acid)

Chemical name: (R, S) -4 - [(2,4-Dihydroxy-3,3-dimethyl-butyryl) amino] calcium butyrate (2: 1).

Dosage form:

capsules.

Description: white hard gelatin capsules No. 0. The contents of the capsules are white or white powder with a yellowish sheen.

Composition: 1 capsule contains:

Active ingredient: rac-Hopantenic acid (D, L-Hopantenic acid) 300.0 mg;

Excipients: microcrystalline cellulose 20.97 mg, magnesium stearate 1.53 mg; hard gelatin capsules No. 0 (capsule composition: titanium dioxide 2%, gelatin up to 100%).

Pharmacotherapeutic group:

nootropic agent.

Pharmacological properties

Pharmacodynamics. The action of Pantogam active is associated with the presence of gamma-aminobutyric acid (GABA) in its structure, which directly affects the GABAb-receptor-channel complex. Pantogam active is a racemic mixture of equal amounts of the R-form of hopantenic acid and its S-isomer. The presence of the isomer improves the transport and interaction of the drug with the GABA receptor. Pantogam active has a more pronounced nootropic and anticonvulsant effect than the first generation hopantenic acid preparations.

Pantogam active increases the brain's resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect. It has anti-asthenic and mild anti-anxiety effects. Reduces motor excitability, regulates behavior. Activates mental activity and performance.

It causes inhibition of the pathologically increased gallbladder reflex and detrusor tone.

Pharmacokinetics.

It is rapidly absorbed from the gastrointestinal tract. Penetrates the blood-brain barrier. It is not metabolized and is excreted unchanged within 48 hours: about 70% of the dose taken - with urine, about 30% - with feces.

Indications for use

cognitive impairment in organic brain lesions (including the consequences of neuroinfections and traumatic brain injuries) and neurotic disorders;

cerebrovascular insufficiency caused by atherosclerotic changes in the vessels of the brain;

extrapyramidal hyperkinesis (myoclonus epilepsy, Huntington's chorea, hepatolenticular degeneration, Parkinson's disease, etc.), as well as for the treatment of extrapyramidal syndrome caused by the use of antipsychotics; with epilepsy, together with anticonvulsants;

psycho-emotional overload, decreased mental and physical performance, to improve concentration and memorization; neurogenic urination disorders (pollakiuria, urgency, urinary incontinence, enuresis); with schizophrenia in complex therapy.

Contraindications

Hypersensitivity, acute severe kidney disease, patient age up to 18 years (there are no clinical studies on the use of the drug at an earlier age).

Application during pregnancy and during breastfeeding

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Method of administration and dosage

Inside, 15-20 minutes after meals, 1-3 capsules (0.3-0.9 g) 2-3 times a day, preferably in the morning and afternoon. The maximum daily dose is 8 capsules (2.4 g). The course of treatment is 1-4 months, sometimes up to 6-12 months. A second course of treatment is possible in 3-6 months.

Side effect

The adverse reactions presented below are listed in accordance with the damage to organs and systems and the frequency of occurrence. The frequency of occurrence is defined as follows: very often (> 1/10), often (> 1/100 and <1/10), infrequently

(> 1/1 000 and <1/100), rarely (> 1/10 000 and <1/1 000), very rarely (<1/10 000, including isolated cases).

Immune system disorders: rarely - allergic reactions (rhinitis, conjunctivitis, skin rashes).

Mental disorders: rarely - sleep disturbances, very rarely - drowsiness.

Nervous system disorders: rarely - headache, very rarely - dizziness, noise in the head.

Gastrointestinal disorders: rarely - nausea, epigastric pain.

In case of disorders of the immune system, the drug is canceled. In other cases, reduce the dose of the drug.

Overdose

Strengthening the symptoms of side effects. Treatment: activated carbon, gastric lavage, symptomatic therapy.

Interaction with other medicinal products

Prolongs the action of barbiturates, enhances the effects of anticonvulsants, prevents side effects of phenobarbital, carbamazepine, antipsychotics. The effect of Pantogam active is enhanced when combined with glycine, etidronic acid. Potentiates the action of local anesthetics (procaine).

special instructions

In conditions of long-term treatment, simultaneous administration of the drug with other nootropic and CNS stimulating agents is not recommended.

Release form

Capsules 300 mg.

10 or 15 capsules in a blister strip made of polyvinyl chloride film and lacquered aluminum foil.

2 or 4 blister packs of 15 capsules or 3 or 6 blister packs of 10 capsules, together with instructions for use, are placed in a cardboard box.

Storage conditions

At a temperature not higher than 25 ? C. Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiration date printed on the package.

Vacation conditions

Dispensed by prescription.